GHRS Company Profile and Key Details

GH Research PLC has 62.03 million shares outstanding. The public float is 20.47 million shares, elevated short interest at 13.27% of float. This equals 2.30 million shares. The short ratio is 6.42 days. Institutional investors hold 102.74% of the float. Insiders own 31.46%.

GHRS has shown sold momentum, gaining 3.55% over the past week and 16.75% over the past quarter, though year-to-date performance is up 24.02%. Short-term trend indicators are bearishly aligned (SMA20 1.12%, SMA50 4.3%, SMA200 12.78%). The stock’s 14-day RSI is 51.54 (neutral), while the ATR of 0.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.89% below its high and over 95.86% above its low. Average 10-day trading volume of 107.32 thousand shares is below the 3-month average of 191.15 thousand, indicating normal recent market interest.

GH Research PLC generated EPS of -$0.73 over the past year. Five-year average earnings growth is -179.37%. The latest quarter delivered EPS of -$0.23. The next quarter is forecast at -$0.27. Next year's EPS is expected at -$39.76. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $70.00 to $19.00. The high target offers 317.41% upside. The low target suggests 13.3% downside. The mean target is $36.40. This offers 117.05% upside. GH Research PLC earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by 0.0%. The prior quarter beat by -31.82%. Over the last six quarters, Apple has recorded several small beats. These include -16.67% in September 03, 2024.

GH Research PLC last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.03. This means the shares are trading above this model’s fair value.

GH Research PLC (NASDAQ:GHRS) closed at $17.40 USD, gaining $0.40 (2.36%) from the previous close of $17.00. The stock is currently mid-range between its 52-week high and low $8.66 and $19.51. With a market capitalization of about $1.08 billion, GH Research PLC is classified as a small-cap and shows market-like volatility (beta ~1.00). Key stats such as the average daily volume over the past year has been around 196.81 thousand shares, in line with its 52-week average. Headquartered in Dublin, None, GH Research PLC operates in the Healthcare sector and the Biotechnology industry. Led by CEO Velichka Valcheva, the company employs approximately 50 people and listed since June 25, 2021. GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders.

GH Research PLC trades at a P/E ratio of -21.59, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.73 trading at moderately above to book value. The P/FCF stands at -23.49, also below market averages.

Our AI price prediction model suggests that GH Research PLC stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.98%, with price expected at $17.27 by April 28, 2026, within a range of $16.54 to $18.05 3-Month Outlook: Projected rise of 69.95%, reaching $28.50 by July 13, 2026, with a range of $27.94 to $29.08. 1-Year Outlook: Projected gain of 14.67%, with price at $19.23 by April 14, 2027, within a range of $18.71 to $20.18.

GH Research PLC (NASDAQ:GHRS) shares are up 24.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows GH Research PLC trading at a premium to the broader market with a P/E of -21.59. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $37.30, suggesting 122.42% upside. Our AI forecast model points to short-term strength (2.98% over two weeks), a medium-term rise (69.95% over three months), and a longer-term gain (14.67% over one year), with expected trading ranges indicating moderate volatility.